Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
NADPH oxidase enzymes (NOX) have been implicated in the development of several diabetic
complications including diabetic nephropathy. GKT137831 is the first in class NOX1/4
inhibitor.
The primary objective of this study is to evaluate the efficacy of oral GKT137831 in patients
with residual albuminuria despite maximal inhibition of the renin angiotensin aldosterone
system.